Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

CORCEPT T Form 4 March 08, 20	THERAPEUTICS	INC									
FORM	4 UNITED S	4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									
Check thi if no long subject to Section 1 Form 4 of Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed purs Section 17(a	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								January 31, 2005 d average ours per a 0.5	
(Print or Type F	Responses)										
ROE ROBERT L Symbo				CEPT THERAPEUTICS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O CORCI INCORPOR MIDDLEFI	EPT THERAPEU ATED, 275	fiddle) TICS	3. Date of (Month/Da 03/04/20	-	insaction			Director X Officer (giv below) Presic		6 Owner er (specify ıry	
Filed(Mont				ndment, Date Original th/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	RK, CA 94025	(7 .)						Person	More than One Re	eporting	
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Date (Month/Day/Year)	Executio any		3. Transactic Code (Instr. 8) Code V	4. Securi mAcquired Disposed (Instr. 3,	ties l (A) o l of (D	or))	quired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-	
Common Stock	03/04/2005			S <u>(1)</u>	1,250	D	\$5	220,557	D		
Common Stock	03/07/2005			S <u>(1)</u>	25	D	\$ 5	220,532	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

1

Edgar Filing: CORCEPT THERAPEUTICS INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships					
1 0	Director	10% Owner	Officer	Other		
ROE ROBERT L C/O CORCEPT THERAPEUTICS INCORPORATED 275 MIDDLEFIELD ROAD MENLO PARK, CA 94025			President and Secretary			
Signatures						
/s/ Fred Kurland, CFO of Corcept Therapeutics Incorpo attorney-in-fact	rated		03/08/2005			
<u>**</u> Signature of Reporting Person			Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 27, 2004.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.